# OFI FUND GLOBAL CONVERTIBLE BOND GI

Monthly Factsheet - Convertible Bonds - May 2020

DEU



### Invesment policy:

Registred in:

OFI Fund - OFI Global Convertible is a global convertible bond subfund of the Luxembourg SICAV OFI Fund. The fund favours convertible issues from companies whose growth potential is linked to their global activity or local leadership.

 Key figures as of 29/05/2020

 NAV of the class GI (EUR):
 103,89

 Net Assets of the class GI (EUR):
 10 389,37

 Total Net Assets (EUR M):
 89,96

 Delta:
 40%

 Modified duration:
 1,65


 Current yield:
 0,61%


 Number of holdings:
 79

### **Characteristics**

ISIN Code: LU2075187869 Europerformance Classification: International convertible bonds OFI Lux Management Company OFI Asset Management Principal distributor advisor: Benchmark (1): Thomson Reuters Global Focus Vanilla Hedge Euro Capital and performance Main Risks: Market : equity, fixed income and credit Fund Manager: Nancy Scribot Blanchet SICAV (UCITS V) under the laws of Luxembourg Legal Form: Canitalisation Distribution Policy: EUR Currency: 25/10/2019 Inception date: Recommended investment horizon: 3 years Daily Valuation: Subscription cut-off: D - 1 at 12h D - 1 at 12h Redemption cut-off: Settlement: D+3 Max/Real Subscription fees: 1%/None Max/Real Redemption fees: None/None Outperformance fees: None 1.23% Ongoing charge: Custodian: SOCIETE GENERALE BANK TRUST LUXEMBOURG SOCIETE GENERALE BANK TRUST LUXEMBOURG Administrative agent:

(1) Benchmark: Thomson Reuters Global Focus Vanilla Hedge Euro





# Return & Volatility

	Since Inception		3 Years (cum.)		1 Year		YTD		6 Months	3 Months
	Return	Volat.	Return	Volat.	Return	Volat.	Return	Volat.	Return	Return
OFI FUND GLOBAL CONVERTIBLE BOND GI	3,89%	15,47%	-	-	-	-	0,65%	14,89%	1,85%	0,76%
Benchmark (1)	5,18%	14,76%	-	-	-	-	1,65%	17,62%	3,73%	1,58%
									Source: F	uroperformance

Monthly returns													
Jan.	Feb.	Mar.	Apr.	Мау	Jun.	Jul.	Aug.	Sep.	Oct.	Nov.	Déc.	Year	Benchmark
									0.07%*	1,94%	1,19%	3,22%	3,27%
0,23%	-0,34%	-8,79%	5,57%	4,63%								0,65%	1,65%
					, , , , , , , , , , , , , , , , , , , ,	Jan. Feb. Mar. Apr. May Jun.	Jan. Feb. Mar. Apr. May Jun. Jul.	Jan. Feb. Mar. Apr. May Jun. Jul. Aug.	Jan. Feb. Mar. Apr. May Jun. Jul. Aug. Sep.	Jan. Feb. Mar. Apr. May Jun. Jul. Aug. Sep. Oct. $0.07\%^*$	Jan. Feb. Mar. Apr. May Jun. Jul. Aug. Sep. Oct. Nov.	Jan. Feb. Mar. Apr. May Jun. Jul. Aug. Sep. Oct. Nov. Déc. 0.07%* 1,94% 1,19%	Jan. Feb. Mar. Apr. May Jun. Jul. Aug. Sep. Oct. Nov. Déc. Year 0.07%* 1,94% 1,19% 3,22%

<sup>\*</sup> Return from 30/10/2019 to 31/10/2019.

Paying Agents: Germany: Paying and Information Agent: OLDENBURGISCHE LANDESBANK AG, Stau 15/17, 26122 Oldenburg. Austria: PAYING AND INFORMATION AGENT: Raiffeisen Bank International AG, Otto Wagner Platz 5 1090 Wien.

This is a non-contractual document provided for information only. This document is intended solely for unitholders or shareholders in the Fund. The information contained in this document is of no contractual value. Only the Fund's full prospectus and latest financial statements shall be deemed legally binding. Past performance is no guarantee of future performance and is not constant over time. Stated performance includes all fees with the exception of subscription and redemption fees. Investors in this fund are exposed to risks associated with changes in the value of units or shares in the Fund arising from market fluctuations. As such, the value of an investment may rise or fall, and investors may consequently lose some or all of their initial investment. This document is provided for information purposes only and is not intended to be either legally binding or contractual in nature. The investor acknowledges having received a copy of the proposectus filed with the AMF prior to investing. In spite of the care taken in preparing this document, the management company cannot guarantee that the information it contains is accurate, complete and up to date. The company may not be held liable for any losses incurred by investors who base their investment decisions solely on this document may not be reproduced in full or in part without the prior consent of its author. All requests for further information about the Fund should be directed to OFI Asset Management, 22 rue Vernier, 75017 Paris, France.

CONTACT • Sales Department • 01 40 68 17 17 • contact@ofi-am.fr



# OFI FUND GLOBAL CONVERTIBLE BOND GI


Monthly Factsheet - Convertible Bonds - May 2020



то	P 10	Holo	dings

Weight Name SERVICENOW 0 2022 06 2,60% DOCUSIGN 0.500 2023\_09 2,40% DASSAULT AVIATION/AIRBUS 0 2021 06 2 31% WORLDLINE 0 2026 07 2.26% STMICROELECTRONICS 0.250 2024 07 2 24% SAREPTA THERAPEUTICS 1.500 2024 11 1.97% SLACK TECHNOLOGIES 0.500 2025 04 1,85% BOOKING HOLDINGS 0.900 2021 09 1 82% RAPID7 2.250 2025 05 1.80% LUMENTUM HOLDINGS 0.250 2024 03 1,77% TOTAL 21,00%

# **Solvency Capital Requirement**



Source: OFI AM

\*Quaterly data as of 30/04/2020 Source: OFI AM

#### **SCR** informations

The aggregate SCR represents the total of all underlying risks. It does not take into account the effects of diversification.

The SCR Market represents the capital requirement taking into account the various risk factors (see correlation matrix arising under reglementation n°2015/35).



## Main movements of the month

Buy / Increase		
Name	Weight M-1	Weight M
WEIMOB 1.500 2025_05	Buy	1,57%
DEXCOM 0.250 2025_11	Buy	1,19%
TELADOC HEALTH 1.250 2027_06	Buy	1,15%
ZHONGSHENG GROUP 0 2025_05	Buy	0,54%

Sell / Decrease		
Name	Weight M-1	Weight M
ECONOCOM GROUP	0,27%	0,18%
DEXCOM 0.750 2022_05	0,90%	Sell
CHINA RAILWAY CONSTRU 0 2021_01	1,09%	Sell
TOHO HOLDINGS 0 2023_06	1,10%	Sell
NIPRO 0 2021_01	1,29%	Sell

Source: OFLAM

Source: OFLAM

## Statistical indicators (compared to the benchmark on a 1 year rolling basis)

Bêta	Alpha	Tracking Error	Sharpe Ratio (2)	Information Ratio	Frequency of profit	Worst draw down
1,01	-0,03	2,36%	0,55	-0,60	71,15%	-14,48%
						Source: Europerformance

(2) Risk free rate: compounded EONIA

### Asset management strategy

Even with countries beginning to ease lockdown restrictions to varying degrees last month, the economic impact of COVID-19 is considerable. The estimated quarter-on-quarter hit to Q1 GDP came out at 2.2% for Germany, 0.9% for Japan, where quarantine measures were less strict, 4.8% for the US and 5.3% each for Italy and France. US retail sales thus plummeted 16.4% MoM, while industrial production fell 11.2%. After the biggest monthly hike in unemployment ever recorded (up from 4.4% to 17.4% in April, with 21 million claimants), the labour market showed no sign of improving (with 10.2 million new claims). In Europe, the picture was the same for retail sales (down 11.2% MoM) and industrial production (down 11.4%), though economic survey results improved slightly as lockdown measures were gradually eased. In China, the first country to emerge from lockdown, industrial production returned to pre-crisis levels but consumer spending continued to lag behind. In light of high levels of uncertainty over international trade, no growth targets were set at the National People's Congress.

Against this backdrop, equities benefited substantially from hopes of a vaccine or treatment, central bank action and the lifting of national lockdowns, ending the month in positive territory everywhere except China, with the MSCI World up 4.6%, the S&P 500 up 4.5%, the Nasdag Biotech up 8.4% and the Nasdag Techno up 7.4%; in Europe, the Euro Stoxx 50 gained 4.7% and the Stoxx 600 put on 3.4%; and in Asia, the Nikkei climbed 8.3%, the Hang Seng fell 6.8%, the Shanghai Composite lost 0.3% and the Kospi was up 4.2%. In credit, the 5-year Crossover in Europe and the 5-year CDX HY in the US both narrowed, down 62 bps to 428 bps and down 67 bps to 566 bps respectively, while German and US 10-year yields tightened slightly, down 14 bps to -0.45% and down 1 bp to 0.65% respectively. In currencies, the euro rose against sterling (up 3.4%), the US dollar (up 1.3%) and the Swiss franc (up 0.9%) on the back of renewed US/China tensions, with the dollar also strengthening against the Japanese yen (up 0.61%), the Chinese yuan (up 1.1%) and the Korean won (up 1.4%). In this environment, convertible bonds gained ground, up 7.4% in the US, 1.6% in Europe, 2.4% in Asia ex Japan and 1.0% in Japan (all measured in euros). All in all, the Thomson Reuters Global Focus Convertibles index in euros gained 5.30% in the month, while OFI Fund Global Convertible Bond gained 4.62% over the same period.

The global primary market surged in the month, with issues totalling \$19.5 billion, beating the May 2001 and December 2007 records. This was mainly thanks to the US region, which on its own racked up \$16.8 billion spread across 36 deals, including DexCom 0.25% 2025 (\$1.2bn; US; healthcare), Teladoc Health 1.25% 2027 (\$1.0bn; US; healthcare), CloudFlare 0.75% 2025 (\$575m; US; technology), Air Canada 4% 2025 (\$748m; Canada; travel and leisure) and Under Armour 1.5% 2024 (\$500m; US; consumer goods). Meanwhile, the European primary market remained open for business, with \$1.5 billion issued, including HelloFresh 0.75% 2025 (€175m; Germany; retail) but also issues from existing issuers like Safran 0.875% 2027 (€800; France; industrial goods and services) and Neoen 2% 2025 (€170m; France; utilities), which issued Europe's first green convertible bond. Lastly, the Asia ex Japan region saw total issues of \$1.2 billion including Weimob 1.5% 2025 (\$150m; China; technology), Zhongsheng 0% 2025 (HKD 4.6bn; China; automotive) and Yageo 0% 2025 (\$180m; Taiwan; industrial goods and services). This brings total issues in the year to date to \$60.8 billion.

As regards performance, the main negative contributors were Lumentum 2024 and 2026 (-21 bps overall; down 7% and 6%) and STM 2024 (-8 bps; down 3.4%), both hit by the impact of renewed US/China tensions on sales of hi-tech products, and Bosideng 2024 (-5 bps; down 6% in line with the retail sector and under the weight of COVID-19 effects). Meanwhile, the top positive contributors were DocuSign 2023 (+54 bps; up 27.5%, buoyed by the widespread adoption of homeworking during lockdown), Top Gloves 2024 (+42 bps; up 56.4% - the leading supplier of surgical gloves saw a surge in orders as fears of a second wave of the epidemic grew, as well as being helped by lower raw materials prices), Sarepta Therapeutics 2024 (+41 bps; up 24%), RH 2023 (+38 bps; up 28.5% on the back of a number of analyst recommendations) and Weimob 2025 (+28 bps; up 20.9%, benefiting directly from the monetisation of WeChat).

In terms of changes, we subscribed for the primary issues DexCom 2022 and Teladoc 2027 in the US and Weimob 2025 and Zhongsheng 2025 in Asia. We sold Toho Holdings 2023, Nipro 2021 and CRCC 2021 to free up some cash and took profits on DexCom 2022 as the company completed its new issue. Lastly, we sold some of our holding of Econocom shares. The geographical breakdown at the month-end was as follows: Europe 30%, US 34%, Asia ex Japan 19% and Japan 9%. The month-end cash position was 8%.

Portfolio equity sensitivity was 40% at end May, the current yield was 0.61% for an average maturity of 3.4 years and the modified duration was 1.86.

Nancy Scribot Blanchet - Fund Manager(s)

This is a non-contractual document provided for information only. This document is intended solely for unitholders or shareholders in the Fund. The information contained in this document is of no contractual value. Only the Fund's full prospectus and latest financial statements shall be deemed legally binding. Past performance is no guarantee of future performance and is not constant over time. Stated performance includes all fees with the exception of subscription and redemption fees. Investors in this fund are exposed to risks associated with changes in the value of units or shares in the Fund arising from market fluctuations. As such, the value of an investment may rise or fall, and investors may consequently lose some or all of their initial investment. This document is provided for information purposes only and is not intended to be either legally binding or contractual in nature. The investor acknowledges having received a copy of the prospectus filed with the AMF prior to investing. In spite of the care taken in preparing this document, the management company cannot guarantee that the information it contains is accurate, complete and up to date. The company may not be held liable for any losses incurred by investors who base their investment decisions solely on this document. The information in this document may not be reproduced in full or in part without the prior consent of its author. All requests for further information about the Fund should be directed to OFI Asset Management, 22 rue Vernier, 75017 Paris, France.


CONTACT • Sales Department • 01 40 68 17 17 • contact@ofi-am.fr




# OFI FUND GLOBAL CONVERTIBLE BOND GI


Monthly Factsheet - Convertible Bonds - May 2020









Source: OFI AM







This is a non-contractual document provided for information only. This document is intended solely for unitholders or shareholders in the Fund. The information contained in this document is of no contractual value. Only the Fund's full prospectus and latest financial statements shall be detailed solely for unitholders or shareholders in the Fund. The information contained in this or shares in the value of units or shares in the Fund arising from market flower information flower in the Fund arising from market flower information and the the Fund arising from market flower information about the Fund arising from market flower information in this document. The information in this document flower flower

CONTACT • Sales Department • 01 40 68 17 17 • contact@ofi-am.fr

